KeaneW.F., EverettE.D., FineR.N., GolperT.A., VasS.I., PetersonP.K.CAPD related peritonitis management and antibiotic therapy recommendations.Perit Dial Bull1987; 7: 55–68.
2.
The Ad Hoc Advisory Committee on Peritonitis Management.Continuous ambulatory peritoneal dialysis (CAPD) peritonitis treatment recommendations: 1989 update.Perit Dial Int1989; 9: 247–56.
3.
KeaneW.F., EverettE.D., GolperT.A., GokalR., HalstensonC., KawaguchiY.Peritoneal dialysis-related peritonitis treatment recommendations. 1993 update. The Ad Hoc Advisory Committee on Peritonitis Management. International Society for Peritoneal Dialysis.Perit Dial Int1993; 13: 14–28.
4.
KeaneW.F., AlexanderS.R., BailieG.R., BoeschotenE., GokalR., GolperT.A.The Ad Hoc Advisory Committee on Peritonitis Management. Peritoneal dialysis related treatment recommendations: 1996 update.Perit Dial Int1996; 16: 557–73.
5.
KeaneW.F., BailieG.R., BoeschotenE., GokalR., GolperT.A., HolmesC.J.Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update [Published erratum appears in Perit Dial Int 2000; 20: 828-9].Perit Dial Int2000; 20: 396–411. See also URL: http://www.ispd.org/guidelines/articles/update/ISPDperitonitis.php3
6.
SheminD., MaazD., St PierreD., KahnS.I., ChazanJ.A.Effect of aminoglycoside use on residual renal function in peritoneal dialysis patients.Am J Kidney Dis1999; 34: 14–20.
FlaniganM., LimV.S.Initial treatment of dialysis associated peritonitis: A controlled trial of vancomycin versus cefazolin.Perit Dial Int1991; 11: 31–7.
9.
ArianoR.E., FranczukC., FineA., HardingG.K., ZelenitskyS.A.Challenging the current treatment paradigm for methicillin-resistant Staphylococcus epidermidis peritonitis in peritoneal dialysis patients.Perit Dial Int2002; 22: 335–8.
10.
LevesqueR., LemieuxC., LaverdiereM., PichetteV.Treatment of gram-positive peritonitis in peritoneal dialysis patients: Cefazolin or vancomycin?Perit Dial Int2003; 23: 599–601.
11.
LupoA., RugiuC., BernichP., LaudonA., MarcantoniC., MosconiG.A prospective, randomized trial of two antibiotic regimens in the treatment of peritonitis in CAPD patients: Teicoplanin plus tobramycin versus cephalothin plus tobramycin.J Antimicrob Chemother1997; 40: 729–32.
12.
VasS.I., BargmanJ., OreopoulosD.G.Treatment in PD patients of peritonitis caused by gram-positive organisms with single daily doses of antibiotics.Perit Dial Int1997; 17: 91–4.
13.
LaiM.N., KaoM.T., ChenC.C., CheungS.Y., ShungW.K.Intraperitoneal once-daily dose of cefazolin and gentamicin for treating CAPD peritonitis.Perit Dial Int1997; 17: 87–8.
14.
KrishnanM., ThodisE., IkonomopoulosD., VidgenE., ChuM., BargmanJ.M.Predictors of outcome following bacterial peritonitis in peritoneal dialysis.Perit Dial Int2002; 22: 573–81.
15.
KhairullahQ., ProvenzanoR., TayebJ., AhmadA., BalakrisnanR., MorrisonL.Comparison of vancomycin versus cefazolin as initial therapy for peritonitis in peritoneal dialysis patients.Perit Dial Int2002, 22: 339–44.
16.
TokarsJ.I., FinelliL., AlterM.J., ArduinoM.J.National surveillance of dialysis-associated diseases in the United States, 2001.Semin Dial2004; 17: 310–19.
17.
ZelenitskyS., ArianoR., HardingG.A re-evaluation of empiric therapy for peritoneal dialysis-related peritonitis.Am J Kidney Dis2004; 44: 559–61.
18.
SepandjF., EriH., GibbA., ReadR., OlsonM.Minimum inhibitory concentration versus minimum biofilm eliminating concentration in evaluation of antibiotic sensitivity of gram-negative bacilli causing peritonitis.Perit Dial Int2004; 24: 65–7.
19.
LiP.K.T., IpM., LawM.C., SzetoC.C., LeungC.B., WongT.Y.Use of intraperitoneal cefepime as monotherapy in treatment of CAPD peritonitis.Perit Dial Int2000; 20: 232–4.
20.
ManleyH.J., BailieG.R., AsherR.D., EiseleG., FryeR.F.Pharmacokinetics of intermittent intraperitoneal cefazolin in CAPD patients.Perit Dial Int1999; 19: 65–70.
21.
GrabeD.W., BailieG.R., EiseleG., FryeR.F.Pharmacokinetics of intermittent intraperitoneal ceftazidime in CAPD patients.Am J Kidney Dis1999; 33: 111–17.
22.
LowC.L., BailieG.R., EvansA., EiseleG., VeneziaR.A.Pharmacokinetics of once-daily ip gentamicin in CAPD patients.Perit Dial Int1996; 16: 379–84.
23.
BailieG.R., EiseleG., VeneziaR.A., YocumD., HollisterA.Prediction of serum vancomycin concentrations following intraperitoneal loading doses in CAPD patients with peritonitis.Clin Pharmacokinet1992; 22: 298–307.
24.
NealD., BailieG.R.Clearance from dialysate and equilibration of intraperitoneal vancomycin in CAPD.Clin Pharmacokinet1990; 18: 485–90.
MulhernJ.G., BradenG.L., O'SheaM.H., MaddenR.L., LipkowitzG.S., GermainM.J.Trough serum vancomycin levels predict the relapse of gram-positive peritonitis in peritoneal dialysis patients.Am J Kidney Dis1995; 25: 611–15.
27.
GoldbergL., ClemengerM., AzadianB., BrownE.A.Initial treatment of peritoneal dialysis peritonitis without vancomycin with a once-daily cefazolin-based regimen.Am J Kidney Dis2001; 37: 49–55.
28.
TroidleL., Gorban-BrennanN., KligerA., FinkelsteinF.Once-daily intraperitoneal cefazolin and oral ciprofloxacin as empiric therapy for the treatment of peritonitis.Adv Perit Dial1999; 15: 213–16.
29.
Diaz-BuxoJ.A., CrawfordT.L., BailieG.R.Peritonitis in automated peritoneal dialysis: Antibiotic therapy and pharmacokinetics.Perit Dial Int2001; 21(Suppl 3): S197–201.
30.
ManleyH.J., BailieG.R.Treatment of peritonitis in automated peritoneal dialysis: Pharmacokinetic principles.Semin Dial2002; 15: 418–21.
PassadakisP., OreopoulosD.The case for oral treatment of peritonitis in continuous ambulatory peritoneal dialysis.Adv Perit Dial2001; 17: 180–90.
33.
DePestelD.D., PeloquinC.A., CarverP.L.Peritoneal dialysis fluid concentrations of linezolid in the treatment of vancomycin-resistant Enterococcus faecium peritonitis.Pharmacotherapy2003; 23: 1322–6.
34.
YeungS.M., WalkerS.E., TailorS.A., AwdishuL., TobeS., YassaT.Pharmacokinetics of oral ciprofloxacin in continuous cycling peritoneal dialysis.Perit Dial Int2004; 24: 447–53.
35.
KowalskyS.F., EcholsR.M., SchwartzM.T., BailieG.R., McCormickE.A.Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD.Clin Nephrol1993; 39: 53–8.
36.
LomaestroB.M., BailieG.R.Absorption interactions with fluoroquinolones: 1995 update.Drug Safety1995; 12: 314–33.
37.
BailieG.R.Morton R, Ganguli L, Keaney M, Waldek S. Intravenous or intraperitoneal vancomycin for the treatment of CAPD-associated gram positive peritonitis?Nephron1987; 46: 316–18.
38.
GoffinE., HerbietL., PouthierD., PochetJ-M, LafontaineJ-J, ChristopheJ-LVancomycin and ciprofloxacin: Systemic antibiotic administration for peritoneal dialysis-associated peritonitis.Perit Dial Int2004, 24: 433–9.
39.
ManleyH.J., BailieG.R., FryeR.F., HessL.D., McGoldrickM.D.Pharmacokinetics of intermittent intravenous cefazolin and tobramycin in automated PD patients.J Am Soc Nephrol2000; 11: 1310–16.
40.
ManleyH.J., BailieG.R., FryeR., McGoldrickM.D.Pharmacokinetics of intermittent intravenous piperacillin in patients treated with automated peritoneal dialysis.Perit Dial Int2000; 20: 686–93.
41.
BakerR.J., SeniorH., ClemengerM., BrownE.A.Empirical aminoglycosides for peritonitis do not affect residual renal function.Am J Kidney Dis2003; 41: 670–5.
42.
NikolaidisP., VasS., LawsonV., Kennedy-VosuL., BernardA., AbrahamG.Is intraperitoneal tobramycin ototoxic in CAPD patients? [Published erratum appears in Perit Dial Int 1991; 11: 285.] Perit Dial Int1991; 11: 156–61.
ElwellR., ManleyH.J., BailieG.R.Correlation of intraperitoneal antibiotic pharmacokinetics with peritoneal membrane transport characteristics.Perit Dial Int2000; 20: 694–8.
45.
ManleyH.J., BridwellD.L., ElwellR.J., BailieG.R.Influence of peritoneal dialysate flow rate on the pharmacokinetics of cefazolin.Perit Dial Int2003; 23: 469–74.
46.
EiseleG., AdewunniC., BailieG.R., YocumD., VeneziaR.Surreptitious use of antimicrobial agents by CAPD patients.Perit Dial Int1993; 13: 313–15.
47.
BailieG.R., KaneM.P.Stability of drug additives in peritoneal dialysate.Perit Dial Int1995; 15: 328–35.
48.
VogesM., FaictD., LechienG., TaminneM.Stability of drug additives in peritoneal dialysis solutions in a new container.Perit Dial Int2004; 24: 590–5.
49.
AllenJ.R., TroidleL.K., JuergensenP.H., KligerA.S., FinkelsteinF.O.Incidence of peritonitis in chronic peritoneal dialysis patients infused with intravenous iron dextran.Perit Dial Int2000; 20: 674–8.
50.
DrusanoG.L.Antimicrobial pharmacodynamics: Critical interactions of “bug and drug.”Nat Rev Microbiol2004; 2: 289–300.
